A Guide to Current Good Radiopharmacy Practices in Radiopharmaceutical Preparation (PET, THERAPY, SPECT)
Journal Title: Nuclear Medicine Seminars - Year 2020, Vol 6, Issue 3
Abstract
Radiopharmaceutical products are inorganic compounds, organic compounds, peptides, proteins, monoclonal antibodies and fragments, and oligonucleotides labeled with radionuclides whose half-life ranges from a few minutes to several days. These radioactive isotopes used for various medical purposes decay spontaneously under ionizing radiation emission. Radiopharmaceuticals cover a wide range of procedures including diagnostics [single photon emission computed tomography (SPECT); and positron emission tomography (PET)], radiation therapy (oncology and palliative pain management), as well as early clinical research and radiolabeled molecule development (e.g. pharmacokinetics, metabolism, receptor binding studies) covers a range of procedures. Unlike conventional medicinal products, RP does not induce pharmacodynamic effects, as small amounts of active ingredients are usually used. Radiopharmaceuticals are classified as medicinal products and therefore they form the basis of the same regulations as non-radioactive medicinal products. In addition to pharmaceutical legislation, laws relating to the manufacture, supply or use of radioactive medicinal products that aim to protect employees, the general public and the environment from radiation need to be followed. The main purpose in good radiopharmacy applications is the safety of the product for medical products and the safety of the patient to whom the product is applied, together with the radiation protection rules. This guide aims to provide an overview of the minimum Good Radiopharmacy Practices (GRP) requirements for radiopharmaceuticals. The manual can also be used as training material for practice, quality control and quality assurance personnel in the field.
Authors and Affiliations
Türkan Ertay
Keywords
Related Articles
- EP ID EP691564
- DOI 10.4274/nts.galenos.2020.0020
- Views 109
- Downloads 0
Renal Toxicity After Radionuclide Therapy
With the introduction of radionuclide therapies, the probability of toxicity has increased in critical organs such as kidney and bone marrow. Although these toxicity rates are relatively low in targeted therapies such as...
F-18 FDG PET/CT Practice Guideline in Oncology: Assesment of Treatment Response
Assessing response to treatment is an important parameter in oncology practice and there is a growing body of evidence for use of F-18 fludeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) t...
Nuclear Medicine in Urinary Tract İnfection
Urinary tract infections (UTIs) are frequent in pediatric population and have various clinical presentations. Definitive diagnosis is made by urinalysis and quantitative urine culture, and antibiotic treatment is usually...
Differentiated Thyroid Carcinoma in Pediatric Age Group/Differences in Diagnosis, Therapy and Follow-up
Differentiated thyroid cancer in childhood is rare. Although its clinical course is quite aggressive with higher rates of lymph node and pulmonary metastases as compared to adults, the final outcome tends to be favorable...
Standardized Reporting of Myocardial Perfusion SPECT Imaging
Myocardial perfusion single photon emission computerized tomography (MPS) report is the final product of a series of complex procedures, starting with patient preparation and ending with interpretation of the process. Th...